✦ LIBER ✦

DNA methylation of HOXD3 as a marker of prostate cancer progression

✍ Scribed by Kron, Ken J; Liu, Liyang; Pethe, Vaijayanti V; Demetrashvili, Nino; Nesbitt, Michael E; Trachtenberg, John; Ozcelik, Hilmi; Fleshner, Neil E; Briollais, Laurent; van der Kwast, Theodorus H

Book ID: 109885539
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 191 KB
Volume: 90
Category: Article
ISSN: 0023-6837
DOI: 10.1038/labinvest.2010.57

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Association of tissue promoter methylati

Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression

✍ Liyang Liu; Ken J. Kron; Vaijayanti V. Pethe; Nino Demetrashvili; Michael E. Nes 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 456 KB

## Abstract Aberrant promoter methylation is known to silence tumor‐suppressor genes in prostate cancer (PCa). We correlated quantitative promoter methylation levels of __APC__, __TGFβ2__ and __RASSF1A__ in 219 radical prostatectomies diagnosed between 1998 and 2001 with clinicopathological follow‐

Trisomy 7: A potential cytogenetic marke

Trisomy 7: A potential cytogenetic marker of human prostate cancer progression

✍ Mark G. Bandyk; Louis L. Pisters; Andrew C. Von Eshenbach; Leland W. K. Chung; L 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 613 KB

## Abstract We used the fluorescence in situ hybridization (FISH) method to show that chromosome 7 trisomy is associated with the progression of human prostate cancer. Thirty‐six specimens including 15 primary prostate carcinomas, 16 metastatic lesions, and 5 normal prostate tissues, as well as 2 p

Genetic pattern of prostate cancer progr

Genetic pattern of prostate cancer progression

✍ Tomo Saric; Zoran Brkanac; Dean A. Troyer; Susan S. Padalecki; Michael Sarosdy; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 71 KB 👁 2 views

Genetic alterations in primary prostate cancer (CaP) have been extensively studied, yet little is known about the genetic mechanisms underlying progression of primary CaP to metastatic prostate cancer. As a result, it is not possible to distinguish clinically indolent localized disease from potentia

Expression of cytokeratin-19 as a marker

Expression of cytokeratin-19 as a marker of neoplastic progression of human prostate epithelial cells

✍ Prasad, S.; Thraves, P.; Dritschilo, A.; Kuettel, M. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 541 KB

## BACKGROUND. Our earlier studies demonstrated neoplastic transformation of SV40immortalized neonatal human prostate epithelial cells (267B1) by fractionated doses of ionizing radiation or by introduction of v-ki-ras oncogene. X-ray-treated 267B1 cells represent three different stages of neoplast

Response to DNA adducts as a marker of c

Response to DNA adducts as a marker of cancer risk?

✍ Frederica Perera; Paolo Vineis 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 21 KB

Endoglin (CD105) as a urinary and serum

Endoglin (CD105) as a urinary and serum marker of prostate cancer

✍ Kazutoshi Fujita; Charles M. Ewing; David Y.S. Chan; Leslie A. Mangold; Alan W. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 105 KB

## Abstract We have previously shown that endoglin (CD105) is upregulated in prostatic fluid of men with large volume prostate cancer. We chose to assess endoglin levels in urine and serum from men with prostate cancer or at increased risk for the disease: Urine samples were collected after digital